Pyxis Oncology, Inc.
NASDAQ:PYXS
4.62 (USD) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2 | 1.836 | 1.251 | 0.444 | 0 |
| Gross Profit
| -2 | -1.836 | -1.251 | -0.444 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 49.586 | 86.129 | 51.054 | 9.048 | 1.224 |
| General & Administrative Expenses
| 32.61 | 37.352 | 18.663 | 3.846 | 1.655 |
| Selling & Marketing Expenses
| -1.776 | 0 | 0 | 0 | 0 |
| SG&A
| 30.834 | 37.352 | 18.663 | 3.846 | 1.655 |
| Other Expenses
| 1.776 | 0 | 0.181 | 0 | 0 |
| Operating Expenses
| 82.196 | 123.481 | 69.717 | 12.894 | 2.879 |
| Operating Income
| -82.196 | -123.481 | -69.717 | -12.894 | -2.879 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 8.406 | 2.764 | -6.258 | 0.066 | 0.107 |
| Income Before Tax
| -73.79 | -120.717 | -75.975 | -12.828 | -2.772 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 1.776 | -2.764 | 5.561 | -0.066 | -0.107 |
| Net Income
| -73.79 | -117.953 | -81.536 | -12.762 | -2.665 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.85 | -3.57 | -2.53 | -0.37 | -0.078 |
| EPS Diluted
| -1.85 | -3.57 | -2.53 | -0.37 | -0.078 |
| EBITDA
| -78.493 | -123.481 | -63.486 | -12.425 | -2.879 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |